Skip to content

Ferring

Active
Public limited companyfounded 198541 years activeLennikse Baan 451, 1070 Anderlecht, BelgiumKBO/BCE: BE 0428.038.135
Summary

The computed 12-month bankruptcy probability of Ferring is 2.0% (moderate). The 2024 annual accounts show equity of €2.6m and a net result of €407,922. Equity is growing by ~5.6% per year across the filed fiscal years. Its solvency ranks better than 38% of 89 sector peers (NACE 21, fiscal year 2024). The company has been active since 1985 and the Belgian State Gazette contains no insolvency or warning signals.

Overview

Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21201Agents specialised in the wholesale of other particular products NACE 46180
#8 oldest company in the Brussels-Capital Region, Pharmaceuticals sector1 site
Size
€20.4mturnover 2024
Staff
15.7 FTE
Equity
€2.6m
Profit
€407,922
Financial health
52 Fair Checked score 2024
Bankruptcy probabilitywithin 12 months
2.0%
Structure
Accounts 69 days overdue3 of 19 deeds read
Why 52- Figures for FY 2024 (filed 16-07-2025)- 1 change of registered office in 24 months- Liquidity: current ratio 1.62, cash €77,368+ Founded in 1985Show the evidence

Checked score

Score 2024
52 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 25% of its sector peers (NACE 21, small)
Financial strength · tick = 2023
Average
Solvency 59-8
equity 34.3% of total assets
Liquidity 19-4
short-term debt 61.5% · cash 1.0%
Profitability 61-3
return on assets 5.3%
Bankruptcy probability, 12 months
2.0% Moderate
0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.5% (43 companies)
Last 24 months 11-2024: 0.3% 12-2024: 0.3%● unchanged vs 11-2024 01-2025: 0.3%● unchanged vs 12-2024 02-2025: 0.3%● unchanged vs 01-2025lowest value 03-2025: 0.3%● unchanged vs 02-2025 04-2025: 0.3%● unchanged vs 03-2025 05-2025: 0.4%▲ +0.1 percentage points vs 04-2025 06-2025: 0.4%● unchanged vs 05-2025 07-2025: 0.4%● unchanged vs 06-2025 08-2025: 0.4%● unchanged vs 07-2025 09-2025: 0.4%● unchanged vs 08-2025 10-2025: 0.4%● unchanged vs 09-2025 11-2025: 0.4%● unchanged vs 10-2025 12-2025: 0.4%● unchanged vs 11-2025 01-2026: 0.4%● unchanged vs 12-2025 02-2026: 0.3%▼ -0.1 percentage points vs 01-2026 03-2026: 0.4%▲ +0.1 percentage points vs 02-2026 04-2026: 0.4%● unchanged vs 03-2026 05-2026: 0.4%● unchanged vs 04-2026 06-2026: 0.5%▲ +0.1 percentage points vs 05-2026 07-2026: 0.5%● unchanged vs 06-2026 08-2026: 0.8%▲ +0.3 percentage points vs 07-2026 09-2026: 1.1%▲ +0.3 percentage points vs 08-2026 10-2026: 2.0%▲ +0.9 percentage points vs 09-2026highest value
Credit up to €130,000 at 30 days acceptable
Liquidity ample (current ratio 1.62 against 1.81 in 2023; short-term debt: 61.5% and cash: 1% of total assets), but 65.7% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, small): better than 23% on solvency, 7% on liquidity, 47% on profitability and 22% on growth.

The bankruptcy probability was computed on 07-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals.
−lowers risk+raises risk○neutral
raises risk · Figures for FY 2024 (filed 16-07-2025)
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian State Gazette
raises risk · Liquidity: current ratio 1.62, cash €77,368
NBB · annual accounts
lowers risk · Founded in 1985
How long the company has existed counts in the probability; how much depends on the rest of its profile.
KBO
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 14-07-2025, 17 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
not confirmed
2024
17 days early
2023
2 days early
2022
5 days early
2021
32 days early
2020
43 days early
2019
94 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 6 accounts on average 32 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
Checked from 2021 on.
KBO publications · our coverage
  1. Resignation: Mario Esteves Durand (director)Appointment: Valerio Trifoni (director) ·…
  2. Resignation: Svetlana Stadnikova (day-to-day manager)Appointment: Perrine Berlier (day-to-day manager)…
  3. Resignation: Jenise Doutsas (director)Appointment: Eric Breumier (director)

Key points

  • Caution: Accounts not fileddeadline was 31-07-2026 69 days late View
  • Positive: Oldest company in the Brussels-Capital Region, Pharmaceuticals sectorin the Checked rankings #8 View
  • Caution: Result fell in 2024from €649,371 to €407,922 ▼ 37.2% View
  • Positive: 7 profitable years in a rowprofit 2024: €407,922 7 years View
  • Board changedlatest change 01-10-2026 · 2 in office 1 joined · 1 left View
  • Known shareholdersaccounts at 31-12-2023 100% View

By topic

Financials

Fiscal year
2024
Turnover
€20.4m
Profit
€407,922
Solvency
34.3%
Turnover▼ 4.9%
Net result
20182024
Go to Financials

Board & ownership

Board
2 members
Known shareholders
100%
  • Eric BreumierDirector
  • Valerio TrifoniDirector
Go to Board & ownership

Timeline

Events
15
Since
2016
  1. 14-07-2025Annual accounts filed
  2. 29-07-2024Annual accounts filed
  3. 26-07-2023Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
Founded
12-02-1985
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.